University of Pennsylvania Researchers used a lentiviral vector designed and manufactured by Lentigen to genetically modify "Serial Killer" T-cells to obliterate tumors in patients with Chronic Lymphocytic Leukemia . Further information on this study can be found at: http://www.uphs.upenn.edu/news/News_Releases/2011/08/t-cells/.
Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer [pdf]